Pasithea Therapeutics Corp. — Director's Dealing 2023

Feb 15, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2022-10-22

Reporting Person: PD Joint Holdings, LLC Series 2016-A (10% Owner)
Reporting Person: Manning Paul B (10% Owner)
Reporting Person: Manning Bradford (10% Owner)
Reporting Person: Tiger Lily Capital, LLC (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2608696	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrant (right to buy)	$1.88	2027-06-21	Common Stock (800000)		Direct